WO2022125006A1 - High drug load compositions of favipiravir - Google Patents
High drug load compositions of favipiravir Download PDFInfo
- Publication number
- WO2022125006A1 WO2022125006A1 PCT/TR2020/051259 TR2020051259W WO2022125006A1 WO 2022125006 A1 WO2022125006 A1 WO 2022125006A1 TR 2020051259 W TR2020051259 W TR 2020051259W WO 2022125006 A1 WO2022125006 A1 WO 2022125006A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- favipiravir
- drug load
- high drug
- immediate release
- pharmaceutical composition
- Prior art date
Links
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical group NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 title claims abstract description 65
- 229950008454 favipiravir Drugs 0.000 title claims abstract description 64
- 229940079593 drug Drugs 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims description 55
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000008203 oral pharmaceutical composition Substances 0.000 claims abstract description 15
- 238000005550 wet granulation Methods 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 18
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 15
- 238000005469 granulation Methods 0.000 claims description 15
- 230000003179 granulation Effects 0.000 claims description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 11
- 239000011230 binding agent Substances 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- 229960000913 crospovidone Drugs 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 8
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 8
- 229920000881 Modified starch Polymers 0.000 claims description 7
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 229940069328 povidone Drugs 0.000 claims description 7
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000007906 compression Methods 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- 235000012239 silicon dioxide Nutrition 0.000 claims description 5
- 241000712461 unidentified influenza virus Species 0.000 claims description 5
- 230000006835 compression Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 229940100688 oral solution Drugs 0.000 claims description 3
- 229940100692 oral suspension Drugs 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 22
- 239000002552 dosage form Substances 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 239000013543 active substance Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 229940126534 drug product Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000025721 COVID-19 Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229940033134 talc Drugs 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- 108091023020 Aldehyde Oxidase Proteins 0.000 description 1
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000009725 powder blending Methods 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Definitions
- the present invention relates to high drug load oral pharmaceutical compositions comprising Favipiravir or its pharmaceutically acceptable salt thereof manufactured by using wet granulation method.
- Favipiravir its chemical name is 6-Fluoro-3-hydroxy-2-pyrazinecarboxamide, is an anti-viral agent that selectively and potently inhibits RNA dependent RNA polymerase (RdRP), which are necessary for the transcription and replication of viral genomes.
- RdRP RNA dependent RNA polymerase
- the empirical formula of Favipiravir is C 5 H 4 FN 3 O 2 and molecular weight is 157.104 g/mole.
- Favipiravir is a white to light yellow powder. It is not hygroscopic at 25°C/51% to 93%RH and is sparingly soluble in acetonitrile and in methanol and slightly soluble in water and in ethanol. It is slightly soluble at pH 2.0 to 5.5 and sparingly soluble at pH 5.5 to 6.
- Favipiravir and its pharmaceutically acceptable salts first have been declared in EPl 112743 by Toyama Chemical Co. Ltd who discovered through screening chemical library for anti-viral activity against the influenza virus.
- Favipiravir was first commercially authorized in Japan to treat cases of influenza that were unresponsive to conventional treatment.
- Favipiravir The innovative product of Favipiravir is currently in the form of tablet form under the name AVIGAN ® in the strength of 200 mg in worldwide. Favipiravir is indicated for the treatment of novel or re-emerging influenza virus infections and also has shown anti-viral activity even against amantadine, oseltamivir and zanamivir resistant influenza viruses in vitro like COVID- 19.
- the recommended term of Favipiravir treatment is 5 -day at the beginning period of its use in COVID-19 treatment.
- the new publications and clinical studies have shown that the term of Favipiravir treatment may be longer for a comprehensive recovery up to 14 days.
- the usual recommended dose of Favipiravir is 1600 mg orally twice daily in the first day of treatment and followed by 600 mg orally twice daily for four days. These doses are administered in two equal amounts daily.
- the recommended total administration period should be at least five days.
- the daily administered dose is very high.
- AVIGAN ® 200 mg Tablet to be administered daily, in the first day is 18 and this number is 6 on the following four days.
- AVIGAN ® is in the form of film-coated tablet contains Favipiravir as active ingredient and povidone, colloidal silicon dioxide, low-substituted hydroxypropyl cellulose, crospovidone, sodium stearyl fumarate, hypromellose, titanium dioxide, talc and yellow ferric oxide as pharmaceutically acceptable excipients.
- Favipiravir is well absorbed orally with bioavailability of approximately 97.6%, plasma protein binding of 54%. Favipiravir is not metabolized by cytochrome P-450 (CYP) enzyme. It is metabolized in liver mostly by aldehyde oxidase and partly to a hydroxylated form by xanthine oxidase. It is excreted in hydroxylated form by kidneys.
- CYP cytochrome P-450
- EP2407166 relates to a pharmaceutical composition
- a pharmaceutical composition comprising Favipiravir or pharmaceutically acceptable salt thereof, a low substituted hydroxypropyl cellulose or croscarmellose sodium and a binder manufactured by a fluidized bed granulation method wherein Favipiravir contained is 50 to 95% of the mass of the tablet or the granulated powder.
- EP2623493 relates to a pharmaceutical composition
- a pharmaceutical composition comprising Favipiravir or pharmaceutically acceptable thereof wherein Favipiravir is in the salt of meglumine salt for the development of an injectable preparation with superior solubility.
- CN111450063 relates to a pharmaceutical composition
- a pharmaceutical composition comprising Favipiravir or pharmaceutically acceptable thereof wherein the prepared granulation contains Favipiravir, filler, suspending agent, sweetener, glidant, and pH regulator wherein Favipiravir has a particle size volume distribution with a D90 less than 40 microns.
- CN107737128 relates to a pharmaceutical composition
- a pharmaceutical composition comprising Favipiravir or pharmaceutically acceptable thereof wherein the prepared granulation contains 200 mg Favipiravir, 24 to 45 mg microcrystalline cellulose, 10 to 18 mg lactose, 8 to 16 mg polyethylene glycol, 0.8 to 1.3 mg sodium lauryl sulfate, 2 to 5 mg fumed silica, and 1 to 2.5 mg magnesium stearate wherein Favipiravir has a particle size volume distribution with a D90 less than 40 microns and D50 between 26 and 33 microns.
- CN 106667926 relates to a pharmaceutical composition comprising Favipiravir or pharmaceutically acceptable thereof wherein the prepared granulation contains Favipiravir, silicified microcrystalline cellulose and a binder.
- the present invention relates to oral pharmaceutical compositions comprising Favipiravir or its pharmaceutically acceptable salt in high drug load and at least one pharmaceutically acceptable excipient as the immediate release dosage form manufactured by using wet granulation method with improved mechanical characteristics which reduces the number of daily administrations.
- the object of this invention is to develop an immediate release composition comprising high and therapeutically effective amounts of Favipiravir or pharmaceutically acceptable salt thereof requiring high drug load in the composition used in the treatment of novel or re-emerging influenza virus infections like COVID-19.
- the daily recommended administration dose of Favipiravir is very high although the present marketed available composition comprises 200 mg Favipiravir per tablet.
- This administration is also recommended to be scheduled in twice daily which means 2 dosage forms of 800 mg could be administered in the morning and 2 dosage forms of 800 mg could be administered in the evening.
- the patients continue to the treatment with only two administrations of 600 mg/dosage form daily for the following remaining duration of the treatment.
- One dosage form of 600 mg can be administered in the morning and one dosage form of 600 mg can be administered in the evening.
- the present invention relates to high drug load pharmaceutical composition comprising Favipiravir and its pharmaceutically acceptable salt in dose of 600 mg.
- the present invention relates to high drug load pharmaceutical composition comprising Favipiravir and its pharmaceutically acceptable salt in dose of 800 mg.
- Favipiravir or pharmaceutically acceptable salt thereof in a small size immediate release oral pharmaceutical compositions are possible for a given dose of Favipiravir which means between 70-80% by weight of the total composition.
- the present invention relates to an immediate release composition comprising Favipiravir and at least one pharmaceutically acceptable excipient manufactured by using wet granulation process.
- the present invention relates to an immediate release composition manufactured by using wet granulation method in which there are two phases named as intra-granular and extra-granular phases.
- Another object of the present invention is to provide a preparation method of a pharmaceutical composition of Favipiravir wherein the pharmaceutical compositions herein disclosed can be manufactured into dosage forms, such as powder, granule, pellet, capsule, tablet, oral solution, oral suspension having desired dissolution profiles.
- Another object of the present invention is to provide pharmaceutical compositions containing Favipiravir by using wet granulation process wherein provided for the manufacture of tablets containing the active ingredient, binder, diluent, disintegrants, glidant and lubricant wherein at least one excipient is present in both phases during manufacturing.
- the present invention provides a pharmaceutical composition comprising high amounts of Favipiravir and at least one pharmaceutically acceptable excipient is developed in the immediate release dosage form with improved pharmaceutical characteristics.
- the present invention is a pharmaceutical formulation contains a "high-load" of drug substance due to the relative large amount of drug substance needed for administration to patients.
- high drug load means that the solid pharmaceutical formulation contains at least 50% by weight, calculated on the basis of the total weight of the formulation, of the active substance.
- high drug load pharmaceutical composition is about patient compliance, because of the route of administration is oral swallowing a product with high total weight of the formulation is very difficult.
- high drug load compositions have the highest therapeutically amount of active substance with design of low total weight of the formulation which makes the composition very dense.
- the present invention is in immediate release form which means it should dissolve or disintegrate in the stomach within a short period of time and present rapid dissolution and absorption to produce rapid onset of action.
- the granulation may be manufactured by the methods like direct compression, dry granulation or wet-granulation before tableting.
- the selection of the manufacture process procedure depends on the physical and mechanical properties of the active ingredient and the excipients.
- the mechanical properties of high drug load finished drug product are dominantly very similar to active ingredient as being the highest amount of ingredient in the total composition. Based on this information, the characterization of active ingredient should be performed intensively. For example, the flowability of powder blend behaves like a powder active ingredient alone. If the flowability of active ingredient is poor the compression and compaction processes could’t be performed successively which means characterization of active ingredient affects the quantitative and qualitative composition and the manufacturing method of finished drug product.
- the solubility values should be minimum 800 mg/250 ml, 3.2 mg/ml to decide the active substance Favipiravir is in highly soluble class.
- Favipiravir is assigned as highly soluble based on the Table-2, since all solubility values in various media are higher than the value of 3.2 mg/ml.
- Favipiravir active substance Another physicochemical property flowability of Favipiravir active substance was identified by performing bulk density and tapped density properties. This analysis was performed according to the details declared in international guidelines.
- the flowability is also effective in defining the proper manufacturing method.
- High favipiravir load powder blend will have the flowability of favipiravir.
- wet granulation refers to converting a powder blend into granules having suitable flow and cohesive properties for tableting.
- the procedure consists of mixing the powders in a suitable blender followed by adding the granulation solution under shear to the mixed powders to complete the granulation process and get a granule to be mixed with other excipients required and to obtain a proper final blend for the compression process. This granulation and many mixing steps involved in wet granulation method will maintain to get a homogenous powder blend.
- the present invention is to provide a pharmaceutical composition comprising favipiravir by using wet granulation method wherein the ingredients of the high drug load immediate release pharmaceutical composition include the active ingredient, release modifying agents, binders, disintegrant, plasticizer, lubricant, glidant, and granulation solvent selected as to be the most suitable excipients with respect to the intended form of administration.
- the ingredients of the high drug load immediate release pharmaceutical composition include the active ingredient, release modifying agents, binders, disintegrant, plasticizer, lubricant, glidant, and granulation solvent selected as to be the most suitable excipients with respect to the intended form of administration.
- the ingredients of the high drug load immediate release pharmaceutical composition include the active ingredient, release modifying agents, binders, disintegrant, plasticizer, lubricant, glidant, and granulation solvent selected as to be the most suitable excipients with respect to the intended form of administration.
- the present invention are in the group comprising powder, granule, pellet, capsule
- suitable fillers may comprise but not limited to dibasic calcium phosphate dehydrate, polysaccharides, primarily microcrystalline cellulose, lactose, mannitol, sugars, sorbitol, sucrose, inorganic salts, primarily calcium salts and the like and mixtures thereof.
- the diluent is microcrystalline cellulose.
- the pharmaceutical composition comprises at least a binder which can be selected from hypromellose, sodium carboxymethyl cellulose, cellulose or cellulose derivatives, povidone, starch, sucrose, polyethylene glycol, or mixtures thereof.
- the binder is povidone.
- the pharmaceutical composition comprises at least a disintegrant which can be selected from croscarmellose sodium, sodium starch glycolate, crospovidone, com starch, pregelatinized starch, low-substituted hydroxypropyl cellulose and microcrystalline cellulose.
- a disintegrant which can be selected from croscarmellose sodium, sodium starch glycolate, crospovidone, com starch, pregelatinized starch, low-substituted hydroxypropyl cellulose and microcrystalline cellulose.
- the disintegrants are crospovidone and pregelatinized starch.
- the glidant is silicon dioxide.
- the pharmaceutical composition comprises at least one lubricant which can be selected from sodium stearyl fumarate, magnesium stearate, calcium stearate talc, stearic acid and mixtures thereof.
- the lubricant is sodium stearyl fumarate.
- Wet granulation process relates to wet massing of the powder blend with a granulation fluid.
- the composition of granulation fluid could be at least one excipient used as binder and a solvent to dissolve it or solely a solvent.
- the granulating fluid contains a solvent which can be volatized easily, so that it can be removed by drying by not requiring high values of temperature.
- the use of binder is used to ensure particle adhesion once the granule is dried. If the drying and subsequent handling is done in a proper conditions of manufacturing and the aggregates will maintain its integrity, the characterization of granule is both denser and more free flowing.
- the overall process of wet granulation consists the manufacturing steps of weighing, powder blending, wet granulating, drying, milling/sieving, lubrication of the blend and compression.
- the pharmaceutical composition comprises at least one granulation fluid which can be selected from deionized water, ethanol and isopropanol, either alone or in combination.
- the granulation solvent is deionized water.
- Example 1 Unit Formula of Example 1
- Step (i) Favipiravir, Microcrystalline Cellulose and half amounts of Crospovidone and Pregelatinized Starch were screened through a proper sieve and transferred into high- shear mixer to stir, ii. Povidone was dissolved in a sufficient amount of deionized water till to dissolve completely, iii.
- the solution in Step (ii) was added into the powder blend prepared in Step (i) to perform granulation process, iv.
- the granules prepared in Step (iii) were dried in fluid bed dryer, v.
- the dried prepared granules in Step (iv) were screened through a proper sieve and stirred, vi.
- Example-1 Another important analytical test to evaluate the characterization of Example-1 was in-vitro dissolution study and the dissolution conditions were designated considering the gastrointestinal pathway of orally applied dosage forms.
- volume of dissolution medium 900 ml
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to high drug load oral pharmaceutical compositions comprising Favipiravir or its pharmaceutically acceptable salt thereof manufactured by using wet granulation method.
Description
HIGH DRUG LOAD COMPOSITIONS OF FAVIPIRAVIR
FIELD OF INVENTION
The present invention relates to high drug load oral pharmaceutical compositions comprising Favipiravir or its pharmaceutically acceptable salt thereof manufactured by using wet granulation method.
BACKGROUND OF THE INVENTION
Favipiravir, its chemical name is 6-Fluoro-3-hydroxy-2-pyrazinecarboxamide, is an anti-viral agent that selectively and potently inhibits RNA dependent RNA polymerase (RdRP), which are necessary for the transcription and replication of viral genomes.
The empirical formula of Favipiravir is C5H4FN3O2 and molecular weight is 157.104 g/mole.
The chemical structure of Favipiravir is shown in the Formula I.
Favipiravir is a white to light yellow powder. It is not hygroscopic at 25°C/51% to 93%RH and is sparingly soluble in acetonitrile and in methanol and slightly soluble in water and in ethanol. It is slightly soluble at pH 2.0 to 5.5 and sparingly soluble at pH 5.5 to 6.
Favipiravir and its pharmaceutically acceptable salts first have been declared in EPl 112743 by Toyama Chemical Co. Ltd who discovered through screening chemical library for anti-viral activity against the influenza virus.
Favipiravir was first commercially authorized in Japan to treat cases of influenza that were unresponsive to conventional treatment.
The innovative product of Favipiravir is currently in the form of tablet form under the name AVIGAN® in the strength of 200 mg in worldwide. Favipiravir is indicated for the treatment of novel or re-emerging influenza virus infections and also has shown anti-viral activity even against amantadine, oseltamivir and zanamivir resistant influenza viruses in vitro like COVID- 19.
The recommended term of Favipiravir treatment is 5 -day at the beginning period of its use in COVID-19 treatment. Moreover, the new publications and clinical studies have shown that the term of Favipiravir treatment may be longer for a comprehensive recovery up to 14 days.
Moreover, the usual recommended dose of Favipiravir is 1600 mg orally twice daily in the first day of treatment and followed by 600 mg orally twice daily for four days. These doses are administered in two equal amounts daily.
The recommended total administration period should be at least five days. The daily administered dose is very high.
The number of AVIGAN® 200 mg Tablet to be administered daily, in the first day is 18 and this number is 6 on the following four days. AVIGAN® is in the form of film-coated tablet contains Favipiravir as active ingredient and povidone, colloidal silicon dioxide, low-substituted hydroxypropyl cellulose, crospovidone, sodium stearyl fumarate, hypromellose, titanium dioxide, talc and yellow ferric oxide as pharmaceutically acceptable excipients.
Favipiravir is well absorbed orally with bioavailability of approximately 97.6%, plasma protein binding of 54%. Favipiravir is not metabolized by cytochrome P-450 (CYP) enzyme. It is metabolized in liver mostly by aldehyde oxidase and partly to a hydroxylated form by xanthine oxidase. It is excreted in hydroxylated form by kidneys.
In the state of art there are many patents/patent applications which are summarized below.
EP2407166 relates to a pharmaceutical composition comprising Favipiravir or pharmaceutically acceptable salt thereof, a low substituted hydroxypropyl cellulose or croscarmellose sodium and a binder manufactured by a fluidized bed granulation method wherein Favipiravir contained is 50 to 95% of the mass of the tablet or the granulated powder.
EP2623493 relates to a pharmaceutical composition comprising Favipiravir or pharmaceutically acceptable thereof wherein Favipiravir is in the salt of meglumine salt for the development of an injectable preparation with superior solubility.
CN111450063 relates to a pharmaceutical composition comprising Favipiravir or pharmaceutically acceptable thereof wherein the prepared granulation contains Favipiravir, filler, suspending agent, sweetener, glidant, and pH regulator wherein Favipiravir has a particle size volume distribution with a D90 less than 40 microns.
CN107737128 relates to a pharmaceutical composition comprising Favipiravir or pharmaceutically acceptable thereof wherein the prepared granulation contains 200 mg Favipiravir, 24 to 45 mg microcrystalline cellulose, 10 to 18 mg lactose, 8 to 16 mg polyethylene glycol, 0.8 to 1.3 mg sodium lauryl sulfate, 2 to 5 mg fumed silica, and 1 to 2.5 mg magnesium stearate wherein Favipiravir has a particle size volume distribution with a D90 less than 40 microns and D50 between 26 and 33 microns.
CN 106667926 relates to a pharmaceutical composition comprising Favipiravir or pharmaceutically acceptable thereof wherein the prepared granulation contains Favipiravir, silicified microcrystalline cellulose and a binder.
The present invention relates to oral pharmaceutical compositions comprising Favipiravir or its pharmaceutically acceptable salt in high drug load and at least one pharmaceutically acceptable excipient as the immediate release dosage form manufactured by using wet granulation method with improved mechanical characteristics which reduces the number of daily administrations.
Summary of the Invention
The object of this invention is to develop an immediate release composition comprising high and therapeutically effective amounts of Favipiravir or pharmaceutically acceptable salt thereof requiring high drug load in the composition used in the treatment of novel or re-emerging influenza virus infections like COVID-19.
The daily recommended administration dose of Favipiravir is very high although the present marketed available composition comprises 200 mg Favipiravir per tablet. Thus, it is advantages if two doses of pharmaceutical compositions containing 800 mg and 600 mg active substance per dosage form are available, so that a patient has to take only four dosages - of 800 mg/dosage form on the first day of the treatment. This administration is also recommended to be scheduled in twice daily which means 2 dosage forms of 800 mg could be administered in the morning and 2 dosage forms of 800 mg could be administered in the evening.
Also, the patients continue to the treatment with only two administrations of 600 mg/dosage form daily for the following remaining duration of the treatment. One dosage form of 600 mg can be administered in the morning and one dosage form of 600 mg can be administered in the evening.
The present invention relates to high drug load pharmaceutical composition comprising Favipiravir and its pharmaceutically acceptable salt in dose of 600 mg.
The present invention relates to high drug load pharmaceutical composition comprising Favipiravir and its pharmaceutically acceptable salt in dose of 800 mg.
The administrations of 600 mg and 800 mg Favipiravir or pharmaceutically acceptable salt thereof in a small size immediate release oral pharmaceutical compositions are possible for a given dose of Favipiravir which means between 70-80% by weight of the total composition.
The present invention relates to an immediate release composition comprising Favipiravir and at least one pharmaceutically acceptable excipient manufactured by using wet granulation process.
The present invention relates to an immediate release composition manufactured by using wet granulation method in which there are two phases named as intra-granular and extra-granular phases.
Another object of the present invention is to provide a preparation method of a pharmaceutical composition of Favipiravir wherein the pharmaceutical compositions herein disclosed can be manufactured into dosage forms, such as powder, granule, pellet, capsule, tablet, oral solution, oral suspension having desired dissolution profiles.
Another object of the present invention is to provide pharmaceutical compositions containing Favipiravir by using wet granulation process wherein provided for the manufacture of tablets containing the active ingredient, binder, diluent, disintegrants, glidant and lubricant wherein at least one excipient is present in both phases during manufacturing.
Detailed Description of the Invention
The present invention provides a pharmaceutical composition comprising high amounts of Favipiravir and at least one pharmaceutically acceptable excipient is developed in the immediate release dosage form with improved pharmaceutical characteristics.
The present invention is a pharmaceutical formulation contains a "high-load" of drug substance due to the relative large amount of drug substance needed for administration to patients. Thus, in the present description, the term "high drug load" means that the solid pharmaceutical formulation contains at least 50% by weight, calculated on the basis of the total weight of the formulation, of the active substance.
The most important advantage of high drug load pharmaceutical composition is about patient compliance, because of the route of administration is oral swallowing a product with high total
weight of the formulation is very difficult. However, high drug load compositions have the highest therapeutically amount of active substance with design of low total weight of the formulation which makes the composition very dense.
The inventors surprisingly found that, administrations of 600 mg and 800 mg Favipiravir or salt thereof in a small size immediate release oral pharmaceutical compositions are possible for a given dose of Favipiravir which means between 70-80% by weight of the active substance calculated on the basis of the total weight of the formulation.
Moreover, the present invention is in immediate release form which means it should dissolve or disintegrate in the stomach within a short period of time and present rapid dissolution and absorption to produce rapid onset of action.
It is known that the granulation may be manufactured by the methods like direct compression, dry granulation or wet-granulation before tableting. The selection of the manufacture process procedure depends on the physical and mechanical properties of the active ingredient and the excipients.
The mechanical properties of high drug load finished drug product are dominantly very similar to active ingredient as being the highest amount of ingredient in the total composition. Based on this information, the characterization of active ingredient should be performed intensively. For example, the flowability of powder blend behaves like a powder active ingredient alone. If the flowability of active ingredient is poor the compression and compaction processes couldn’t be performed successively which means characterization of active ingredient affects the quantitative and qualitative composition and the manufacturing method of finished drug product.
The characterization studies were performed with the investigation of active substance solubility at die beginning. The identification of solubility will be used to define components and the manufacturing method of finished drug product. In addition, it will give opportunity to predict in vitro - in vivo correlation.
Table-1: Solubility results in simulated gastric or intestinal fluids
The lowest solubility was observed in pH 1.2 medium and the highest solubility value was observed in pH 6.8 medium.
The results were evaluated with the table given in the international guidelines. The solubility test was carried out by dissolving the maximum amount of active substance in 250 ml simulated gastric or intestinal fluids. It is to be assumed that this could also influence the permeability criterion as defined by the Biopharmaceutics Classification System (BCS).
In the various guidance documents, different definitions of the dose strength to be used for establishing the Dose/Solubility (D/S) ratio can be found. The highest dosage strength of a marketed immediate release drug product to be used, the World Health Organization (WHO) and European Medicine Agency (EMA) guidance define that the D/S ratio should be established with the highest single dose (which could consist of administering multiple dosage forms to achieve a required dose).
The solubility values should be minimum 800 mg/250 ml, 3.2 mg/ml to decide the active substance Favipiravir is in highly soluble class.
Table-2: Solubility results of Favipiravir active substance
Favipiravir is assigned as highly soluble based on the Table-2, since all solubility values in various media are higher than the value of 3.2 mg/ml.
Another physicochemical property flowability of Favipiravir active substance was identified by performing bulk density and tapped density properties. This analysis was performed according to the details declared in international guidelines.
Table-3: Results of flowability
Table-4: Scale of flowability
The results were also evaluated based on the reference table, Table-4, given in the international guidelines and the flowability of Favipiravir was assigned as poor.
An equilibrium should be obtained between the relationship of the composition and manufacturing method. The first property to be improved to manage the manufacturing processes successfully was flowability. This could be possible with the selection of proper excipients.
The flowability is also effective in defining the proper manufacturing method. High favipiravir load powder blend will have the flowability of favipiravir.
The term “wet granulation” refers to converting a powder blend into granules having suitable flow and cohesive properties for tableting. The procedure consists of mixing the powders in a suitable blender followed by adding the granulation solution under shear to the mixed powders to complete the granulation process and get a granule to be mixed with other excipients required and to obtain a proper final blend for the compression process. This granulation and many mixing steps involved in wet granulation method will maintain to get a homogenous powder blend.
In one of the preferred embodiment of the present invention is to provide a pharmaceutical composition comprising favipiravir by using wet granulation method wherein the ingredients of the high drug load immediate release pharmaceutical composition include the active ingredient, release modifying agents, binders, disintegrant, plasticizer, lubricant, glidant, and granulation solvent selected as to be the most suitable excipients with respect to the intended form of administration.
In some embodiments of the present invention are in the group comprising powder, granule, pellet, capsule, tablet, oral solution, oral suspension dosage forms.
In a preferred embodiment, suitable fillers may comprise but not limited to dibasic calcium phosphate dehydrate, polysaccharides, primarily microcrystalline cellulose, lactose, mannitol, sugars, sorbitol, sucrose, inorganic salts, primarily calcium salts and the like and mixtures thereof. Preferably, the diluent is microcrystalline cellulose.
In a preferred embodiment, the pharmaceutical composition comprises at least a binder which can be selected from hypromellose, sodium carboxymethyl cellulose, cellulose or cellulose derivatives, povidone, starch, sucrose, polyethylene glycol, or mixtures thereof. Preferably, the binder is povidone.
In a preferred embodiment, the pharmaceutical composition comprises at least a disintegrant which can be selected from croscarmellose sodium, sodium starch glycolate, crospovidone, com starch, pregelatinized starch, low-substituted hydroxypropyl cellulose and microcrystalline cellulose. Preferably, the disintegrants are crospovidone and pregelatinized starch.
In silicon dioxide, powdered cellulose, talc, tribasic calcium phosphate. Preferably, the glidant is silicon dioxide.
In a preferred embodiment, the pharmaceutical composition comprises at least one lubricant which can be selected from sodium stearyl fumarate, magnesium stearate, calcium stearate talc, stearic acid and mixtures thereof. Preferably, the lubricant is sodium stearyl fumarate.
Wet granulation process relates to wet massing of the powder blend with a granulation fluid. The composition of granulation fluid could be at least one excipient used as binder and a solvent to dissolve it or solely a solvent.
The granulating fluid contains a solvent which can be volatized easily, so that it can be removed by drying by not requiring high values of temperature. The use of binder is used to ensure particle adhesion once the granule is dried. If the drying and subsequent handling is done in a proper conditions of manufacturing and the aggregates will maintain its integrity, the characterization of granule is both denser and more free flowing. The overall process of wet granulation consists the manufacturing steps of weighing, powder blending, wet granulating, drying, milling/sieving, lubrication of the blend and compression.
In a preferred embodiment, the pharmaceutical composition comprises at least one granulation fluid which can be selected from deionized water, ethanol and isopropanol, either alone or in combination. Preferably, the granulation solvent is deionized water.
In one of the embodiments of the present invention is formulated in tablet dosage form.
Example 1: Unit Formula of Example 1
The detailed manufacturing steps were presented below: i. Favipiravir, Microcrystalline Cellulose and half amounts of Crospovidone and Pregelatinized Starch were screened through a proper sieve and transferred into high- shear mixer to stir, ii. Povidone was dissolved in a sufficient amount of deionized water till to dissolve completely, iii. The solution in Step (ii) was added into the powder blend prepared in Step (i) to perform granulation process, iv. The granules prepared in Step (iii) were dried in fluid bed dryer, v. The dried prepared granules in Step (iv) were screened through a proper sieve and stirred, vi. Silicon dioxide and the rest amount of the Crospovidone and Pregelatinized Starch were screened through a proper sieve and added into the powder blend prepared in Step (v), vii. Sodium Stearyl Fumarate was screened through a proper sieve and added into the powder blend prepared in Step (vi) and stirred to obtain a uniform final blend, viii. Tablet compression was performed with the final blend in Step (vii).
It was observed that the flowability of the high drug load pharmaceutical composition manufactured by using wet granulation method of the final blend was improved.
Another important analytical test to evaluate the characterization of Example-1 was in-vitro dissolution study and the dissolution conditions were designated considering the gastrointestinal pathway of orally applied dosage forms.
The dissolution study was performed under the conditions presented below:
Medium: pH 6.8 phosphate buffer
Volume of dissolution medium: 900 ml
Temperature: 37°C±0.5°C Rotation speed: 100 rpm Apparatus: Paddle Run time: 60-minute
Table 5: The results of dissolution study of Example 1
While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.
Claims
1. A high drug load immediate release oral pharmaceutical composition comprising Favipiravir or a pharmaceutically acceptable salt thereof manufactured by using wet granulation method, wherein the range of Favipiravir is between 70-80% by weight of the total composition.
2. A high drug load immediate release oral pharmaceutical composition according to Claim 1, wherein the composition comprises 600 mg Favipiravir.
3. A high drug load immediate release oral pharmaceutical composition according to Claim 1, wherein the composition comprises 800 mg Favipiravir.
4. A high drug load immediate release oral pharmaceutical composition according to claim
3, wherein the composition is administered for twice daily in the first day of the treatment.
5. A high drug load immediate release oral pharmaceutical composition according claim 2, wherein the composition is administered for twice daily in the following days of the treatment after the first day.
6. A high drug load immediate release oral pharmaceutical composition according to any of the preceding claims, wherein the composition is in the form of a powder, a granule, a pellet, a capsule, a tablet, an oral solution or an oral suspension.
7. A high drug load immediate release oral pharmaceutical composition of Claim 6, wherein the composition further comprises microcrystalline cellulose as a filler, povidone as a binder, and sodium stearyl fumarate as a lubricant.
8. A high drug load immediate release oral pharmaceutical composition according to any of the preceding claims wherein the composition comprises:
Favipiravir 70.0 - 80.0% by weight of the total composition
Microcrystalline Cellulose 8.0 - 10.0% by weight of the total composition
Crospovidone 3.0 - 5.0% by weight of the total composition
Povidone 3.0 - 5.0% by weight of the total composition
Silicon Dioxide 0.1 - 0.8% by weight of the total composition
Sodium Stearyl Fumarate 0.1 - 0.5% by weight of the total composition
Pregelatinized Starch 6.0 - 9.0% by weight of the total composition
Deionized water Quantity sufficient
9. A high drug load immediate release oral pharmaceutical composition according to any of the preceding claims, wherein the wet granulation process comprises the steps of: i. Favipiravir, Microcrystalline Cellulose and half amounts of Crospovidone and Pregelatinized Starch were screened through a proper sieve and transferred into high-shear mixer to stir, ii. Povidone was dissolved in a sufficient amount of deionized water till to dissolve completely, iii. The solution in Step (ii) was added into the powder blend prepared in Step (i) to perform granulation process, iv. The granules prepared in Step (iii) were dried in fluid bed dryer, v. The dried prepared granules in Step (iv) were screened through a proper sieve and stirred, vi. Silicon dioxide and the rest amount of the Crospovidone and Pregelatinized Starch were screened through a proper sieve and added into the powder blend prepared in Step (v), vii. Sodium Stearyl Fumarate was screened through a proper sieve and added into the powder blend prepared in Step (vi) and stirred to obtain a uniform final blend, viii. Tablet compression was performed with the final blend in Step (vii).
10. A high drug load immediate release oral pharmaceutical composition according to any of the preceding claims for use in the treatment of novel or re-emerging influenza virus infections.
11. A dosage regime according to claims 1-10, wherein the dosage regime comprises administering the composition comprises 800 mg Favipiravir twice daily in the first day of the treatment, and adminitering 600 mg Favipiravir twice daily in the following days.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2020/051259 WO2022125006A1 (en) | 2020-12-08 | 2020-12-08 | High drug load compositions of favipiravir |
| EP20965250.2A EP4259141A4 (en) | 2020-12-08 | 2020-12-08 | High drug load compositions of favipiravir |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2020/051259 WO2022125006A1 (en) | 2020-12-08 | 2020-12-08 | High drug load compositions of favipiravir |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022125006A1 true WO2022125006A1 (en) | 2022-06-16 |
Family
ID=81974489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2020/051259 WO2022125006A1 (en) | 2020-12-08 | 2020-12-08 | High drug load compositions of favipiravir |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP4259141A4 (en) |
| WO (1) | WO2022125006A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106667926A (en) * | 2015-11-09 | 2017-05-17 | 石药集团中奇制药技术（石家庄）有限公司 | Favipiravir tablets and preparation method thereof |
| RU2731932C1 (en) * | 2020-05-07 | 2020-09-09 | Общество с ограниченной ответственностью "Кромис" (ООО "Кромис") | Anti-covid-19 (sars-cov-2) viral pharmaceutical composition |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI463999B (en) * | 2009-03-13 | 2014-12-11 | Toyama Chemical Co Ltd | Tablets and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide |
| WO2022115055A1 (en) * | 2020-11-27 | 2022-06-02 | Santa Farma Ilac Sanayii A.S. | Immediate release composition of favipiravir |
-
2020
- 2020-12-08 WO PCT/TR2020/051259 patent/WO2022125006A1/en unknown
- 2020-12-08 EP EP20965250.2A patent/EP4259141A4/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106667926A (en) * | 2015-11-09 | 2017-05-17 | 石药集团中奇制药技术（石家庄）有限公司 | Favipiravir tablets and preparation method thereof |
| RU2731932C1 (en) * | 2020-05-07 | 2020-09-09 | Общество с ограниченной ответственностью "Кромис" (ООО "Кромис") | Anti-covid-19 (sars-cov-2) viral pharmaceutical composition |
Non-Patent Citations (2)
| Title |
|---|
| BAI, C. Q. ET AL.: "Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705)-Sierra Leone, 2014", CLINICAL INFECTIOUS DISEASES, vol. 63, no. 10, 2016, pages 1288 - 1294, XP055951453 * |
| See also references of EP4259141A4 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4259141A1 (en) | 2023-10-18 |
| EP4259141A4 (en) | 2024-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016272881C1 (en) | Solid dosage forms of palbociclib | |
| RU2405540C1 (en) | Tablet with high content of medication | |
| KR101699912B1 (en) | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix | |
| BR112020024107A2 (en) | pharmaceutical combination, composition, and combination preparation comprising glucokinase activator and sglt-2 inhibitor and methods of preparing and using them | |
| AU757547B2 (en) | Novel compositions of eprosartan | |
| JP2010536798A (en) | Method and composition for controlling bioavailability of poorly soluble drugs | |
| EP2291079A2 (en) | Formulations for cathepsin k inhibitors | |
| JP7428356B2 (en) | Pharmaceutical compositions of sorafenib with high bioavailability, oral solid preparations of sorafenib, and uses thereof | |
| WO2013189305A1 (en) | Valsartan-amlodipine compound solid preparation and preparation method therefor | |
| CN113633616A (en) | Solid preparation with high bioavailability | |
| WO2022115055A1 (en) | Immediate release composition of favipiravir | |
| US20030022928A1 (en) | Novel compositions of eprosartan | |
| EP4058025A1 (en) | Pharmaceutical compositions comprising ticagrelor | |
| EP4259141A1 (en) | High drug load compositions of favipiravir | |
| US20090030057A1 (en) | Pharmaceutical composition of telmisartan | |
| US20230225977A1 (en) | Formulation comprising daprodustat | |
| US11648242B2 (en) | Pharmaceutical composition comprising pimavanserin, process of preparation and use thereof | |
| JP6669937B2 (en) | Pharmaceutical composition of 5-HT6 antagonist | |
| WO2022042646A1 (en) | Lurasidone hydrochloride composition and preparation method therefor | |
| KR102330953B1 (en) | Pharmaceutical dosage forms containing sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olate | |
| WO2018202224A1 (en) | Film-coated tablets of deferasirox | |
| JP2019073488A (en) | Pharmaceutical tablets containing aprepitant as active ingredient | |
| WO2016139681A2 (en) | Pharmaceutical composition of tizanidine and process for preparing the same | |
| TW202435886A (en) | Milvexian pharmaceutical compositions | |
| WO2023080854A1 (en) | Lurasidone hydrochloride compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20965250 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2020965250 Country of ref document: EP Effective date: 20230710 |